A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine

IntroductionFor complete or functional cure of hepatitis B virus (HBV) infection, application of immunotherapy is now being attempted. Recently, we reported that a 6-mer hepatitis B virus (HBV)-derived peptide, Poly6, exerts a strong anticancer effect in tumor-implanted mice through inducible nitric...

Full description

Bibliographic Details
Main Authors:	Yu-Min Choi, Dong Hyun Kim, Junghwa Jang, Bum-Joon Kim
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Immunology
Subjects:	hepatitis B virus (HBV) therapeutic vaccination adjuvant type 1 interferon (IFN-I) (HBV)-derived peptide Poly6
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1155637/full

Similar Items

Effect of S-region mutations on HBsAg in HBsAg-negative HBV-infected patients
by: Hui Liu, et al.
Published: (2024-04-01)

Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01)

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
by: Yael Gozlan, et al.
Published: (2022-03-01)

Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy
by: Yasuhito Tanaka, et al.
Published: (2024-05-01)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
by: Maryam Moini, et al.
Published: (2022-03-01)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
by: Shaowen Jiang, et al.
Published: (2023-01-01)

Global prevalence and molecular characteristics of three clades within hepatitis B virus subgenotype C2: Predominance of the C2(3) clade in South Korea
by: Dong Hyun Kim, et al.
Published: (2023-03-01)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
by: Carlotta Cerva, et al.
Published: (2022-02-01)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
by: Zhan Zeng, et al.
Published: (2023-01-01)

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report
by: Maki Ohkubo, et al.
Published: (2023-12-01)

Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV
by: Zhuoyan Lei, et al.
Published: (2024-12-01)

HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality
by: Julia Peña-Asensio, et al.
Published: (2024-03-01)

A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner
by: Yu-Min Choi, et al.
Published: (2021-06-01)

Serological and molecular characterization of HBV infection with HBsAg reactive and HBV DNA non-reactive
by: Chunxiang LI, et al.
Published: (2022-09-01)

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients
by: Xin Liu, et al.
Published: (2023-08-01)

Analysis of S gene characteristic sequences and changes in properties of protein expression in HBV ASCs with low-level HBsAg
by: Yu Yu, et al.
Published: (2022-09-01)

Serological characteristics of HBsAg positive/HBV DNA non-reactive blood donors
by: Yuanyuan JING, et al.
Published: (2024-04-01)

Role of hepatitis B virus non-structural protein HBx on HBV replication, interferon signaling, and hepatocarcinogenesis
by: Fei Wang, et al.
Published: (2023-12-01)

rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome
by: Hyein Jeong, et al.
Published: (2021-03-01)

Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers
by: Romina Salpini, et al.
Published: (2020-11-01)

Interferon and interferon-stimulated genes in HBV treatment
by: Qirong Li, et al.
Published: (2022-12-01)

Detection and prevalence of HBsAg and HBV DNA among visiting patients attending health facilities in Nigeria
by: Uchenna D. Abazuh, et al.
Published: (2023-07-01)

HBV Core Protein Enhances Cytokine Production
by: Tatsuo Kanda, et al.
Published: (2015-09-01)

Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg
by: Silvia Meschi, et al.
Published: (2024-03-01)

Characteristics analysis of HBV serological markers of NAT reactive blood donors under different HBsAg status
by: Dequn NI, et al.
Published: (2023-01-01)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
by: Romina Salpini, et al.
Published: (2020-01-01)

Characteristics of HBcrAg in HBsAg-/HBV DNA+ blood donors in Wuxi area
by: Yan WANG, et al.
Published: (2024-01-01)

Correlation between quantitative HBsAg and quantitative HBV DNA in chronic hepatitis B patients: a systematic review and meta-analysis
by: Ummi Maimunah, et al.
Published: (2024-05-01)

Editorial: HBV and lymphoma
by: Giuseppe Gentile, et al.
Published: (2023-07-01)

Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
by: Lanlan Liu, et al.
Published: (2024-07-01)

RESULTS OF GENOTYPING HEPATITIS VIRUS B IN HBsAg-NEGATIVE BLOOD DONORS IN ASTANA, KAZAKHSTAN
by: Yu. V. Ostankova, et al.
Published: (2018-01-01)

HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation
by: Lorenzo Piermatteo, et al.
Published: (2021-09-01)

An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients
by: Minghui Li, et al.
Published: (2022-08-01)

End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients
by: Sylvia M. Brakenhoff, et al.
Published: (2023-02-01)

HBsAg loss with HBsAg/anti-HBs seroconversion and non-detectable HCV-RNA in a patient with chronic HBV e-minus/HCV hepatitis treated with two cycles of antiviral therapy
by: Antonio Salvio, et al.
Published: (2012-01-01)

Potential infectivity of blood from HBsAG asymptomatic carriers due to the presence of HBV-DNA and comparison with other markers of hbv infection Potencial de infectividade em sangue de portadores assintomáticos de HBsAg caracterizado pela presença de HBV-DNA e comparação com outros marcadores da Hepatite B.
by: M. Valeria Tedeschi, et al.
Published: (1989-12-01)

Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapy
by: Romina Salpini, et al.
Published: (2025-01-01)

Quantitative dynamic evaluation HBsAg in blood in comparison to viral load level in patients with chronic HBV-monoinfection
by: K. R. Dudina, et al.
Published: (2011-06-01)

The Culprit Behind HBV-Infected Hepatocytes: NTCP
by: Li S, et al.
Published: (2024-10-01)